- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- September 2021
- 120 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- August 2022
United States
From €1872EUR$1,940USD£1,606GBP
- Report
- August 2022
Global
From €763EUR$790USD£654GBP
- Report
- February 2021
Global
From €2857EUR$2,960USD£2,451GBP
- Clinical Trials
- November 2021
- 425 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- February 2021
- 45 Pages
Global
From €3373EUR$3,495USD£2,894GBP
- Report
- January 2021
- 38 Pages
Global
€1272EUR$1,318USD£1,091GBP
- Report
- October 2023
- 103 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- May 2023
- 112 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- October 2022
- 133 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- November 2020
- 139 Pages
Global
From €1930EUR$2,000USD£1,656GBP
The Gout Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Gout drugs are used to reduce the inflammation and pain associated with gout, a type of arthritis caused by the buildup of uric acid in the joints. These drugs can be taken orally or injected directly into the affected joint. Commonly prescribed gout drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine.
Gout drugs are typically prescribed by a doctor and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the form in which it is taken.
Some companies in the Gout Drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more
